Form 8-K IVERIC bio, Inc. For: Sep 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Form 8-K IVERIC bio, Inc. For: Sep 06
September 6, 2022 12:14 PM EDT
Stifel analyst Annabel Samimy reiterated a Buy rating and $28.00 price target on Iveric Bio (NASDAQ: ISEE) following the release of GATHER-2 (G2) Zimura data that hit high statistical significance on its primary endpoint of mean rate of GA growth (slope) for both square root transformation and... More
September 6, 2022 10:33 AM EDT
Credit Suisse analyst Tiago Fauth raised the price target on Iveric Bio (NASDAQ: ISEE) to $27.00 (from $24.00) while maintaining a Outperform rating.
The analyst comments "Competitive Dynamic Nuanced, but Valuation Gap Still Favors ISEE Shares. We expect the debate to now shift to... More
September 6, 2022 8:24 AM EDT
Apellis Pharmaceuticals (NASDAQ: APLS) weakness appears related to data from IVERIC bio (NASDAQ: ISEE) in geographic atrophy
lSEE +28%APLS -4.3%...
More
September 6, 2022 7:32 AM EDT
Guggenheim analyst Eddie Hickman reiterated a Buy rating on Iveric Bio (NASDAQ: ISEE).
The analyst comments "This morning, ISEE announced that GATHER 2 met its primary endpoint showing a 14.3% reduction in mean rate of growth (slope) over 12 months (reduction was 17.7% was used using observed GA area. We note that while the drug... More
